医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Announced: Regarding the Synergistic Effects of Our Complete Subsidiary Acquisition of Biopta Limited

2015年11月26日 PM10:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

ReproCELL, Inc. (JASDAQ: 4978) announces that at a director meeting held on November 24th, 2015, the complete subsidiary acquisition of English company Biopta Limited (hereafter referred to as Biopta) was decided upon.

Our company group has up to now been involved in the global development of research reagent products and cell products through its use of cutting edge techniques involving human iPS cells, and continues healthy business expansion in said market, which is showing remarkable development.

Biopta, the company purchased, offer a drug development support service targeted at the drug industry, and can boast to having dealings with 8 of the top 10 mega pharma companies. The drug development support service offered by Biopta is an outsourcing business that, through human cell activities, carries out research and tests for exploratory research and preclinical testing, which up until now were carried out using animal testing. This field’s potential market size is expected to rise to ¥1,750,000,000,000, and is attracting a lot of attention. The biggest strength of the company is its ability to use the network of medical institutions that it owns across England and America to acquire very fresh human tissue and internal organs in a timely manner. From this abundant cell lineup, the company can pick up human tissue and internal organs requested at the preclinical trial stage of drug development, allowing it to offer an outsourced drug development support service that is desirable to individual clients.

Through this purchase, Biopta’s drug development support service joins the business lineup of our company group, allowing us to target pharmaceutical companies, covering both providing products and delegated research. Further, making use of the synergy of our company group’s global, cutting edge iPS cell cultivation technology and Biopta’s GLP certified equipment and its high level of service knowhow in using it, as a new part of our business we can start on the early stages of an unprecedented “preclinical test service business using iPS cells” and create a real competitive superiority.

For more information,visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005046/en/

CONTACT

ReproCELL, Inc. (JASDAQ Company code: 4978)
Chikafumi Yokoyama,
+81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究